Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial.
By L. Gianni, U. Dafni, R. Gelber, E. Azambuja, S. Muehlbauer, A. Goldhirsch, M. Untch, I. Smith, J. Baselga, C. Jackisch and 15 more. The Lancet Oncology, 2011
640 citations recorded by the source corpus.
Subfields: Cancer Research, Oncology, Pathology and Forensic Medicine
View Paper: https://www.semanticscholar.org/paper/3b7d0f43ac8c0fc1829cf26d8b878ab52dd75f6a
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Cancer Research
Citations in the corpus
- A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS). (2015, background): “subsequent access to the superior arm are contaminated, subsequently late intention to treat (ITT) follow-up data are not evaluable [37, 38].”
- Early dissemination seeds metastasis in breast cancer (2016, neutral): “However, only circumstantial knowledge is available about MRD and systemic (adjuvant) therapies consequently improve outcome in only about 20% of patients 3,4 .”
- Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. (2013, background): “Since 2005, several of the first-generation adjuvant trials have been updated and have confirmed the disease-free and overall survival benefit offered by 1 year of trastuzumab administered with or after adjuvant chemotherapy.(29-31) Prospective randomized trials, first reported in abstract form in l”